2022
DOI: 10.1182/blood-2022-159467
|View full text |Cite
|
Sign up to set email alerts
|

Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
6
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(7 citation statements)
references
References 0 publications
1
6
0
Order By: Relevance
“…A limitation of the present study was our relatively small cohort size relative to other historic MRD analyses in the literature, limiting our capacity to perform subgroup analyses. However, we note that the number of patients in our cohort was comparable to existing MRD evaluations of ven/aza patients, 24,26,28 with the exception of the VIALE-A cohort. 23 Ours is also the most comprehensive molecular MRD analysis of ven/aza patients to date.…”
Section: Discussionsupporting
confidence: 61%
See 2 more Smart Citations
“…A limitation of the present study was our relatively small cohort size relative to other historic MRD analyses in the literature, limiting our capacity to perform subgroup analyses. However, we note that the number of patients in our cohort was comparable to existing MRD evaluations of ven/aza patients, 24,26,28 with the exception of the VIALE-A cohort. 23 Ours is also the most comprehensive molecular MRD analysis of ven/aza patients to date.…”
Section: Discussionsupporting
confidence: 61%
“…23 Ours is also the most comprehensive molecular MRD analysis of ven/aza patients to date. 27,28 Although our data suggest that the receipt of SCT did not fully explain the beneficial effects of ddPCR MRD-negative status in our cohort, given our small sample sizes we cannot fully rule out that disease biology or patient factors such as age do not impact our results. Therefore, to enable more in-depth subset analysis we are continuing these studies in ven/aza patients.…”
Section: Discussionmentioning
confidence: 74%
See 1 more Smart Citation
“…Patients who did not achieve BM MRD clearance in the first 6 months of treatment showed poorer survival in a real-world data set. 39 MRD status in the PB also appeared prognostic, which if confirmed would have important practical implications for monitoring (Recommendation 7). Larger studies will be required to more accurately define the most important thresholds and checkpoints in this molecular subgroup, where a subset of patients show particularly prolonged survival with venetoclaxbased regimens.…”
Section: Montesinos Et Al Randomized 146 Patients With Newly Diagnosedmentioning
confidence: 99%
“…Preliminary evidence indicates that molecular assessment of NPM1 MRD in BM by RT‐qPCR is prognostic in patients treated with venetoclax‐based therapies ( Recommendation 6 ). Patients who did not achieve BM MRD clearance in the first 6 months of treatment showed poorer survival in a real‐world data set 39 . MRD status in the PB also appeared prognostic, which if confirmed would have important practical implications for monitoring ( Recommendation 7 ).…”
Section: Recommendations For Assay Selectionmentioning
confidence: 99%